Participating Companies

Akouos [AKUS] US$702 MM MCap
Res­tor­ing and pre­serv­ing high-acu­i­ty hear­ing is one of the great­est un­met chal­lenges of medicine: 360 mil­lion peo­ple world­wide have dis­abling hear­ing loss, but there are no FDA-ap­proved ther­a­pies to ad­dress it. [more in­for­ma­tion]
Alka­h­est is a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pany ded­i­cat­ed to treat­ing neu­rode­gen­er­a­tive and age-re­lat­ed dis­eas­es with trans­for­ma­tive ther­a­pies tar­get­ing the ag­ing plas­ma pro­teome. Alka­h­est is de­vel­op­ing nov­el plas­ma-based ther­a­pies in col­lab­o­ra­tion with Gri­fols, a glob­al health­care com­pany and lead­ing pro­duc­er of plas­ma ther­a­pies. [more in­for­ma­tion]
Alloplex Biotherapeutics
Our lead on­col­o­gy pro­gram us­es pro­pri­e­tary leuko­cyte ac­ti­va­tor cell (LAC) lines, which are en­gi­neered from a paren­tal tu­mor cell line, to spe­cif­i­cal­ly en­gage and ac­ti­vate pe­ripher­al blood mononu­clear cells (PBMC) through through na­tive re­cep­tors. [more in­for­ma­tion]
AM-Pharma B.V.
Treat­ing sep­sis as­so­ci­at­ed acute kid­ney in­jury (AKI) with pro­pri­e­tary re­com­bi­nant al­ka­line phos­pha­tase (re­cAP). Re­sults from Ph 2 trial in 300+ pts, de­mon­s­trat­ed rel­a­tive im­prove­ment of 40%+ OS in re­cAP group. Ini­ti­at­ing Ph 3 in Q3 2020 – in­ter­im look (n=400) exp Q3 2021 (P end­point: Day 28 all-cause mor­tal­i­ty). [more in­for­ma­tion]
Phase 3 ready, Tevere­lix, a long act­ing in­jectable pep­tide GnRH an­ta­g­on­ist. Lead in­di­ca­tion for pros­tate can­cer, fol­lowed by be­nign pro­stat­ic hy­per­pla­sia (BPH), acute uri­nary re­ten­tion (AUR), uterine fi­broids and en­dometrio­sis. Over 450 sub­jects have been dosed over 850 times to date with no se­ri­ous ad­verse re­ac­tions and good lo­cal tol­er­ance. [more in­for­ma­tion]
CD40 ag­on­ist mAb; 170+ pts dosed (mono & com­bi sett­ings). 7 on­go­ing Ph 2s, undis­closed oc­u­lar dis­ease pro­gram in Ph 3. AACR: Ph 1b da­ta (w/Park­er Inst); col­labs w/BMY, MDACC, Yale, et al [more in­for­ma­tion]
Clin­i­cal stage de­vel­op­ment of Anti­gen Re­cep­tor Com­plex T-cells (ARC-T) that are read­i­ly si­lenced, ac­ti­vat­ed and re­pro­grammed in vi­vo by ad­min­is­tra­tion of a tu­mo-tar­get­ing anti­gen pro­tean called a sparX. Backed by NEA, No­vo, SR One, Take­da, So­las­ta, Quan, Clough, Mi­rae, JVC and LG. [more in­for­ma­tion]
Axial Biotherapeutics, Inc.
The com­pany's bio­ther­a­peu­tics prod­ucts har­ness the gut-brain axis to de­vel­op nov­el Cen­tral Ner­vous Sys­tem (CNS) Ther­a­peu­tics to im­prove the qual­i­ty of life for peo­ple with CNS dis­eas­es and di­s­or­ders, pro­vid­ing med­i­cal pro­fes­sio­n­als and health­care in­sti­tu­tions with a new ap­proach for di­ag­nos­ing and treat­ing PD and ASD and po­ten­tial­ly other CNS dis­eas­es. [more in­for­ma­tion]
Cadent Therapeutics
Ca­dent Ther­a­peu­tics is cre­at­ing break­through ther­a­pies for the treat­ment of move­ment di­s­or­ders and cog­ni­tive im­pair­ment. The com­pany has an ex­clu­sive li­cense and col­lab­o­ra­tion agree­ment with No­var­tis to de­vel­op a neg­a­tive al­los­ter­ic mo­d­u­la­tor, now in Phase 1 clin­i­cal studies for the treat­ment of treat­ment re­sis­tant de­pres­sion. [more in­for­ma­tion]
Checkmate Pharmaceuticals
Check­mate’s lead prod­uct can­di­date, CMP-001, is an in­vesti­ga­tio­n­al can­cer im­munother­a­peu­tic that has been shown to re­v­erse re­sis­tance to PD-1 ther­a­py in some pa­tients. [more in­for­ma­tion]
Chondrial Therapeutics
Chon­drial’s lead com­pound is CTI-1601, which the Com­pany is de­vel­op­ing as a po­ten­tial treat­ment for Frie­dreich’s Ataxia. CTI-1601 is de­signed to de­liv­er the fra­taxin pro­tein to the mi­to­chon­dria of pa­tients with Frie­dreich’s Ataxia, who, due to a ge­net­ic ab­nor­mal­i­ty, are un­able to pro­duce this es­sen­tial pro­tein. [more in­for­ma­tion]
Confo Therapeutics
Con­fo Ther­a­peu­tics is a pi­oneer­ing bio­phar­ma­ceu­ti­cal com­pany build­ing a port­fo­lio of best-in-class small molecule medicines for the treat­ment of or­phan and rare dis­eas­es us­ing its pro­pri­e­tary Con­fo® tech­nol­o­gy, a pro­pri­e­tary GPCR con­for­ma­tion-sen­si­tive drug dis­cov­ery en­gine. [more in­for­ma­tion]
Cornea­Gen is a mis­sion-driv­en com­pany com­mitt­ed to trans­form­ing how corneal sur­geons treat and care for the cornea. Cornea­Gen sup­ports corneal sur­geons and their pa­tients with a spec­trum of ser­vices, in­clud­ing the lat­est in in­no­va­tive prod­ucts, de­liv­ery of the high­est qual­i­ty tis­sue, sur­geon ed­u­ca­tion, and ad­vo­ca­cy for pa­tient ac­cess and re­im­burse­ment poli­cies. [more in­for­ma­tion]
Dy­nacure is a clin­i­cal-stage drug de­vel­op­ment com­pany fo­cused on im­prov­ing the lives of pa­tients with rare and or­phan dis­eas­es. The Dy­nacure team lev­er­ages its proven track re­cord in rare dis­ease drug de­vel­op­ment to build a pipe­line of nov­el drugs. [more in­for­ma­tion]
Evox Therapeutics
Ex­o­some-based drugs have the po­ten­tial to ad­dress some of the lim­i­ta­tions of pro­tein, anti­body and nu­cle­ic acid-based ther­a­pies by en­abling de­liv­ery to cells and tis­sues that are cur­rent­ly out of reach us­ing other drug de­liv­ery tech­nolo­gies, and Evox is lead­ing the de­vel­op­ment within this emerg­ing ther­a­peu­tic space. [more in­for­ma­tion]
Impact Therapeutics Inc
Based in Chi­na, IM­PACT is com­mitt­ed to the dis­cov­ery and de­vel­op­ment of best-in-class ther­a­peu­tics to treat can­cer and other life-threat­en­ing dis­eas­es. IM­PACT is a clin­i­cal-stage com­pany with a unique small-molecule drug dis­cov­ery and de­vel­op­ment plat­form tar­get­ing DDR. IM­PACT's lead­ing pro­gram, PARP in­hibi­tor IM­P4297, is cur­rent­ly un­der­go­ing phase I trials in Aus­tralia and Chi­na. [more in­for­ma­tion]
iTeos Therapeutics SA
iTeos Ther­a­peu­tics is a pri­vate­ly-held, clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany ded­i­cat­ed to ex­tend­ing and im­prov­ing the lives of can­cer pa­tients by de­sign­ing and de­vel­op­ing next gen­er­a­tion im­munother­a­pies. The Com­pany ad­vanced EOS100850, an in­sur­mount­able and non-brain pen­e­trant adeno­sine A2A re­cep­tor an­ta­g­on­ist, in­to a Phase I trial in Jan­uary 2019. [more in­for­ma­tion]
Kineta Inc.
Kine­ta (Pri­vate) - whol­ly owned pre­clin­i­cal an­ti-VIS­TA (in­nate im­mune tar­get) anti­body re­pro­grams the tu­mor mi­croen­vi­ron­ment and is dif­fer­en­ti­at­ed from other im­munother­a­pies by block­ing sup­pres­sive cells in cold tu­mors. $520M deal with Pfiz­er for its small molecule RIG-I im­munother­a­py and $360M+ deal with Ge­nen­tech for KCP506, pre­clin­i­cal, non-opi­oid for chron­ic pain. [more in­for­ma­tion]
Klox Technologies, Inc.
Pro­pri­e­tary bio­pho­ton­ic sys­tem uti­l­izes mul­ti-LED ar­ray and chro­mophore con­vert­er gel to pro­mote skin re­pair. Acne & skin re­ju­ve­na­tion in­di­ca­tion ap­proved in EU and Ca­na­da, on­go­ing trials in wound heal­ing. [more in­for­ma­tion]
Landos Biopharma
Based on ex­ten­sive pre­clin­i­cal studies, Lan­dos has vali­dat­ed a unique mech­anism of ac­tion in­volv­ing LAN­CL2 that ex­erts po­tent an­ti-in­flam­ma­to­ry ef­fects with an out­s­tand­ing safe­ty pro­file. Lead as­set BT-11 Phase 2 in­ter­im read out in mid-2020 in UC. [more in­for­ma­tion]
Minoryx Therapeutics
Oral PPAR&gam­ma; ag­on­ist, MIN-102, in Piv­o­tal Ph 2/3 for X-linked ALD and Ph 2 Frie­drich’s Ataxia; da­ta for both ex­pect­ed by end of 2020. VC in­ves­tors in­clude Kur­ma, Ysios, Fund+, Roche, Id­in­vest, etc [more in­for­ma­tion]
Neurana Pharmaceuticals
The pri­mary ob­jec­tive of the study was to as­sess the ef­fi­ca­cy of vari­ous dai­ly dos­es of tolperi­sone to de­ter­mine the dose to be used for the planned Phase 3 clin­i­cal pro­gram. Giv­en the pos­i­tive re­sults of the STAR Study, Neu­ra­na plans to conduct an end-of-Phase 2 meet­ing with the FDA in the first quar­ter of 2020 and ini­ti­ate Phase 3 clin­i­cal studies of tolperi­sone lat­er in 2020. [more in­for­ma­tion]
De­vel­op­er of can­cer ther­a­pies in­tend­ed to im­prove long-term sur­vi­val of can­cer pa­tients world­wide. The com­pany's ther­a­py of­fers im­mune-mo­d­u­la­to­ry mon­o­clo­n­al anti­body com­bined with im­mune check­point in­hibi­tors, en­abling med­i­cal com­pa­nies to im­prove pa­tients health. [more in­for­ma­tion]
Pandion Therapeutics
A biotech­nol­o­gy com­pany de­vel­op­ing bis­pe­cif­ic anti­body ther­a­peu­tics to achieve lo­cal­ized im­muno­mo­d­u­la­tion at the site of dis­ease for durable, tis­sue-spe­cif­ic treat­ment of pa­tients with au­toim­mune and in­flam­ma­to­ry dis­ease and or­gan tran­s­plants. [more in­for­ma­tion]
Rexgenero Ltd.
The com­pany’s lead can­di­date, REX-001, is a high­ly in­no­va­tive au­tol­o­gous cell ther­a­py that is be­ing studied in a Phase III clin­i­cal pro­gram in pa­tients with crit­i­cal limb is­chemia (CLI) with di­a­betes, a poor­ly treat­ed dis­ease with a high risk of am­pu­ta­tion and death. [more in­for­ma­tion]
Sensei Biotherapeutics
The com­pany is us­ing its pro­pri­e­tary drug dis­cov­ery plat­form, called SPIR­IT, to dis­cov­er and de­vel­op both vaccines and T-cell ther­a­pies, in­clud­ing SN­S301, its clin­i­cal stage can­cer vaccine, and SNS-723, its cell ther­a­py pro­gram in pre­clin­i­cal de­vel­op­ment for solid tu­mors and he­ma­to­log­i­cal can­cers. [more in­for­ma­tion]
Sigilon Therapeutics, Inc.
Plat­form cell ther­a­py com­pany fo­cus­ing on sev­er­al chron­ic dis­eas­es (he­mophilia, T1D, ly­so­so­mal stor­age di­s­or­ders); 5 INDs exp in the next 2 years; 1st IND in Jan 2020 (He­mophilia A). Eli Lil­ly col­lab­o­ra­tion in T1D ($75m ini­tial com­mit­ment, $410 mile­s­tones & sin­gle to dou­ble dig­it roy­al­ties). En­gi­neer­ing cells to pro­duce cru­cial pro­teins/en­zymes/etc; en­cap­su­late cells in al­gi­nate sphere co­va­lent­ly bond­ed w/coat­ing that pre­vents fi­bro­sis & re­jec­tion; coat­ing dev'd at Bob Langer's Lab at MIT. Flag­ship Pi­oneeri [more in­for­ma­tion]
Solebury Trout
With al­most two de­cades of ex­pe­ri­ence in the biotech­nol­o­gy, phar­ma­ceu­ti­cal, med­i­cal tech­nol­o­gy and life sci­ence tech­nol­o­gy sec­tors, the Trout Group of­fers its clients the knowl­edge base need­ed to clar­i­fy in­vest­ment themes and lev­er­age key re­la­tion­ships for in­creased ex­po­sure to the prop­er au­di­ence. [more in­for­ma­tion]
Sonnet Biotherapeutics, Inc. [SONN] US$31 MM MCap
Son­net's in­ter­leukin-based can­di­date has been shown to en­hance pK (up to 10 fold) and im­prove tu­mor de­liv­ery with an in­crease in in vi­vo ef­fi­ca­cy (30 fold) as de­mon­s­trat­ed in a mice tu­mor mod­el. The Son­net plat­form de-risks the use of in­ter­leukins by great­ly ex­tend­ing their in vi­vo half-life, while al­so im­prov­ing their spe­ci­fic­i­ty to tu­mor tis­sue. [more in­for­ma­tion]
sterna biologicals
By tar­get­ing tran­scrip­tion fac­tors that play a cen­tral role in reg­u­lat­ing Th1- and Th2-driv­en in­flam­ma­to­ry mech­anisms, the Com­pany’s pro­pri­e­tary DNAzyme-based drug can­di­dates can in­ter­vene with up­stream in­flam­ma­to­ry pro­cess­es to ad­dress re­lat­ed dis­eas­es more ef­fec­tive­ly. Ster­na cur­rent­ly has four pro­grams in phase 2 de­vel­op­ment. [more in­for­ma­tion]
Tarveda Therapeutics
is dis­cov­er­ing and de­vel­op­ing a new class of po­tent and se­lec­tive mi­nia­ture drug con­ju­gates (Pen­tarins®) for the treat­ment of pa­tients with a wide range of solid tu­mors. PEN-221 is a mi­nia­ture drug con­ju­gate in clin­i­cal eval­u­a­tion for the treat­ment of pa­tients with so­ma­to­s­tatin re­cep­tor 2 (SSTR2) ex­press­ing neu­roen­docrine, small cell lung and other solid tu­mors. [more in­for­ma­tion]
TAVEC Pharmaceuticals
Our ex­o­somes are pre­pared to spe­cif­i­cal­ly tar­get can­cer cells and de­liv­er their ge­net­ic pay­loads to ef­fect max­i­mum dis­rup­tion on can­cer growth. We pro­duce spe­cial­ized types of ex­o­somes that are se­lec­tive­ly tak­en up by can­cer cells and can be used to de­liv­er tu­mor sup­pres­sive miR­NAs and other dis­rup­tive molecules to can­cer cells with min­i­mal ef­fects on nor­mal tis­sue. [more in­for­ma­tion]
Tempest Therapeutics
Tem­pest Ther­a­peu­tics is a de­vel­op­men­t‐s­tage biotech­nol­o­gy com­pany ad­vanc­ing small molecules that mo­d­u­late an­ti‐­tu­mor im­mu­ni­ty path­ways. The com­pany has a bal­anced and deep pipe­line con­sist­ing of first‐in‐­class and po­ten­tial best‐in‐­class small molecule ther­a­peu­tics that mo­d­u­late dist­inct im­mune re­sponse path­ways rel­e­vant to mount­ing an ef­fec­tive an­ti‐­tu­mor re­sponse. [more in­for­ma­tion]
TRIGR Therapeutics
Bis­pe­cif­ic Abs: du­al an­gio­ge­n­e­sis in­hibi­tor (TR009) and 3 im­muno­mo­d­u­la­to­ry du­al check­point & T cell en­gag­ing Bs­Abs. AS­CO TR009 P1a re­sults. In­ter­im P1a dose es­ca­la­tion: clin ben­e­fit of 66%, one PR (7.5mg) no DLTs in solid tu­mors [more in­for­ma­tion]
Vaccitech Limited
Pro­pri­e­tary ChA­dOx (prime) and MVA (boost) tech­nol­o­gy plat­form in­duces and main­tains CD8+ T-cells at the max­i­mum lev­els pub­lished to date. Ph1/2 da­ta for HPV and HBV im­munother­a­pies ex­pect­ed 2H20. En­cour­ag­ing pros­tate can­cer, 5T4 im­munother­a­peu­tic da­ta re­cent­ly re­leased. Ph1/2 NS­CLC MAGE-NYE­SO im­munother­a­peu­tic en­ters clin­ic in Q1 2021. ChA­dOx COVID-19 vaccine out-li­censed to Ox­ford Uni/As­traZene­ca with post-pan­dem­ic rev­enue stream. $150M fund­ing at Jen­n­er In­sti­tute and com­pany raised $48M since for­ma­tion [more in­for­ma­tion]
Viracta Therapeutics, Inc.
Virac­ta is a clin­i­cal-stage drug de­vel­op­ment com­pany fo­cused on ad­vanc­ing nov­el epi­ge­net­ic ther­a­peu­tics de­rived from its pro­pri­e­tary Kick & Kill ther­a­peu­tic ap­proach to ben­e­fit pa­tients with vi­ral-as­so­ci­at­ed can­cers and other se­ri­ous dis­eas­es. Virac­ta plans to en­ter in­to ad­di­tio­n­al ge­o­graph­ic and com­bi­na­tion ther­a­py part­n­er­ships. [more in­for­ma­tion]
Vyome Therapeutics Inc.
$22M fund raise Jan '19. Ad­vanced lead as­set VB-1953 to Ph 2 for mod­er­ate to se­vere acne. Pipe­line DART - du­al ac­tion over­com­ing an­timi­cro­bial re­sis­tance - and MRT - pa­tent­ed an­ti­fun­gal plat­form. Treat drug-re­sis­tant skin patho­gens. [more in­for­ma­tion]
Xenikos BV
T-Guard has been grant­ed FDA Fast Track Desig­na­tion for the treat­ment of steroid-re­frac­to­ry acute Graft-ver­sus-Host Dis­ease (SR-aGVHD), and is en­ter­ing piv­o­tal Ph3 studies in the U.S. Xenikos is head­quar­tered in the Nether­lands, has estab­lished a sub­si­diary at the East Coast US to pur­sue a go-it-alone strat­e­gy in the US. [more in­for­ma­tion]
Yisheng Biopharma
De­vl bio­ther­a­peu­tics for can­cers and in­fec­tious dis­ease. Prod­ucts in de­vt in­clude Ph 1 IO prod­uct tar­get­ing solid tu­mors Ph 3 PI­KA vaccine tar­get­ing hep B and ra­bies in­fec­tions. [more in­for­ma­tion]